Beta Bionics, Inc. (BBNX)
NASDAQ: BBNX · Real-Time Price · USD
11.18
+0.24 (2.19%)
Apr 17, 2025, 4:00 PM EDT - Market closed

Beta Bionics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022
Period Ending
Dec '24 Dec '23 Dec '22
Net Income
-54.76-44.1-64.75
Depreciation & Amortization
2.282.092.09
Other Amortization
--0.01
Loss (Gain) From Sale of Assets
0.020.010.04
Loss (Gain) From Sale of Investments
-2.91-0.75-
Stock-Based Compensation
6.385.666.1
Provision & Write-off of Bad Debts
0.070.05-
Other Operating Activities
12.789.9-0.91
Change in Accounts Receivable
-7.62-4.49-
Change in Inventory
-11.44-1.19-
Change in Accounts Payable
1.520.72-0.08
Change in Unearned Revenue
2.460.34-0.18
Change in Other Net Operating Assets
2.94-0.68-2.53
Operating Cash Flow
-48.27-32.45-60.21
Capital Expenditures
-3.4-0.4-0.77
Sale of Property, Plant & Equipment
0.0500
Investment in Securities
-0.13-69.3-
Investing Cash Flow
-3.48-69.69-0.77
Issuance of Common Stock
0.10.030.39
Other Financing Activities
-4.15-11.41
Financing Cash Flow
55.62101.0356.78
Net Cash Flow
3.87-1.11-4.2
Free Cash Flow
-51.67-32.85-60.98
Free Cash Flow Margin
-79.34%-273.84%-34067.04%
Free Cash Flow Per Share
-8.12-6.19-12.20
Levered Free Cash Flow
-35.24-19.66-
Unlevered Free Cash Flow
-35.24-19.66-
Change in Net Working Capital
12.234.6-
Updated Mar 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q